Evidence regarding lncRNAs involvement in endocrine resistance also comes from individual studies, and the scientific efforts made so far have resulted in the identification of at least five oncogenic lncRNAs (HOTAIR, BCAR4, UCA1, CCAT2, ROR) and a single suppressor tumor, GAS5 in the clinical setting of BC endocrine therapy resistance (Table 4). This evidence concerns the gene CCAT2 and breast cancer.